Pyxis Oncology (PYXS) to Release Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Pyxis Oncology to post earnings of ($0.32) per share for the quarter.

Pyxis Oncology Price Performance

PYXS stock opened at $1.16 on Tuesday. The company’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $2.42. The firm has a market capitalization of $68.98 million, a PE ratio of -1.13 and a beta of 1.11. Pyxis Oncology has a 12 month low of $0.99 and a 12 month high of $6.18.

Institutional Trading of Pyxis Oncology

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE increased its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 53,745 shares of the company’s stock after acquiring an additional 9,062 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 as of its most recent filing with the SEC. 39.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PYXS has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.